TTOO - T2 Biosystems stock rises ~9% premarket on plans to develop diagnostic test for monkeypox

• T2 Biosystems ( NASDAQ: TTOO ) stock jumped 8.8% to $0.14 in Tuesday premarket trading, after the company said it was exploring plans to develop a rapid molecular diagnostic test to detect monkeypox.
• T2's announcement comes just days after the U.S. government declared the current monkeypox outbreak a public health emergency , in an attempt to improve awareness and raise more funding to fight the viral disease.
• "A rapid and accurate diagnosis of monkeypox is essential to expedite treatment and to limit exposure and spread of the disease," TTOO said in Tuesday's statement .
• Other pharmaceutical companies have recently announced plans to provide more tests for monkeypox or start drug development programs to fight the disease, such as Todos Medical ( OTCQB:TOMDF ) and NanoViricides ( NNVC ).
• Other monkeypox test makers: Co-Diagnostics ( CODX ), Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), Applied DNA Sciences ( APDN ), Virax Biolabs Group ( VRAX ).

For further details see: